Research and Markets: Cystic Fibrosis - A Comprehensive Global Strategic Business Report

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/ebb846/cystic_fibrosis) has announced the addition of the "Cystic Fibrosis - Global Strategic Business Report" report to their offering.

This report analyzes the US market for Cystic Fibrosis in Millions of US$. Annual estimates and forecasts are provided for the period of 2007 through 2015. Also, a six-year historic analysis is provided for this market. The report profiles 56 companies including many key and niche players such as Abbott Laboratories, Axcan Pharma, Inc., Digestive Care, Inc., Gilead Sciences, Inc., Eurand N.V., Inspire Pharmaceuticals, Inc., KaloBios Pharmaceuticals, Inc., Nektar Therapeutics, PTC Therapeutics, Inc., Transave, Inc., Vertex Pharmaceuticals, Inc., Actelion Ltd., F. HoffmannLa Roche Ltd., Novartis AG, and Pharmaxis Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

Key Topics Covered:

I. Introduction, Methodology & Product Definitions

II. A US Market Report

1. Market Overview

2. Cystic Fibrosis Treatment: An Overview

3. Research In Cystic Fibrosis Space

4. Pipeline Analysis

5. Disease Overview

6. Research And Development Initiatives Of Companies

7. Recent Industry Activity

8. Product Approvals

9. Focus On Select Global Players

10. US Market Perspective

III. Competitive Landscape

Companies Mentioned:

  • Abbott Laboratories (USA)
  • Axcan Pharma Inc. (Canada)
  • Digestive Care, Inc. (USA)
  • Gilead Sciences, Inc. (USA)
  • Eurand N.V. (The Netherlands)
  • Inspire Pharmaceuticals, Inc. (USA)
  • KaloBios Pharmaceuticals, Inc. (USA)
  • Nektar Therapeutics (USA)
  • PTC Therapeutics, Inc. (USA)
  • Transave, Inc. (USA)
  • Vertex Pharmaceuticals, Inc. (USA)
  • Actelion Ltd. (Switzerland)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Novartis AG (Switzerland)
  • Pharmaxis Ltd. (Australia)

For more information visit http://www.researchandmarkets.com/research/ebb846/cystic_fibrosis.



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   Australia  United States  Europe  North America  Canada  Australia/Oceania  Switzerland

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Professional Services  Other Professional Services

MEDIA:

Logo
 Logo

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.